Overall survival was statistically significantly improved in adults treated with tislelizumab/chemotherapy compared with placebo/chemotherapy. The Food and Drug ...
Response to Biologics in Patients With Early-Onset Treatment-Naïve Metastatic Colorectal Cancer—An Aide et Recherche en Cancérologie Digestive Database Analysis Overall, 240 patients were randomly ...
The US Food and Drug Administration (FDA) has approved tislelizumab-jsgr (Tevimbra, BeiGene, Ltd.) as second-line monotherapy for certain adult patients with unresectable or metastatic esophageal ...
Tevimbra combined with chemotherapy showed significant survival benefits in esophageal cancer, reducing the risk of death by 34% in a phase 3 trial. Keytruda, combined with Herceptin and chemotherapy, ...
BASKING RIDGE, N.J. & RAHWAY, N.J.--(BUSINESS WIRE)-- The first patient has been dosed in the IDeate-Esophageal01 phase 3 trial evaluating the efficacy and safety of investigational ifinatamab ...
Expression levels of LINC00115 were analyzed in 96 paired ESCC tumor and adjacent normal tissues using RT-qPCR. In vitro assays, including CCK-8, colony formation, wound healing, Transwell migration, ...
ctDNA MRD testing may spot hidden relapse and guide treatment holidays in metastatic gastroesophageal cancer, as deep ctDNA ...
Lenvima and Keytruda with chemotherapy did not significantly improve OS in metastatic ESCC compared to Keytruda and chemotherapy alone. Median OS was 17.6 months in the Lenvima arm versus 15.5 months ...
ctDNA monitoring in esophageal and gastroesophageal cancers may detect recurrence earlier than traditional methods, offering a minimally invasive and sensitive approach. The Signatera assay showed ...
Douglas Graham cancer patient with stage 4 metastatic esophageal cancer gets to ring the bell after his 8th session of chemo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results